Related Experiment Videos
CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease
Gregor Auf1, Lin Chen, Paul Fornès
1Fédération de Neurologie Mazarin and Institut National de la Santé et de la Recherche Médicale (INSERM) U-495, Hôpital de la Salpêtrière, 75013, Paris, France.
Abstract:
Oligodeoxynucleotides containing CpG motifs (CpG-ODN) are powerful immunostimulating agents that are currently entering clinical trials in various human diseases. Concerns exist about potential auto-immune diseases triggered by such treatment. We thus investigated whether tumor rejection induced by CpG-ODN treatment could lead to a harmful auto-immune reaction against the nervous system (neurological paraneoplastic disease) at the time of acute tumor rejection, or in long-term surviving animals. Mice bearing established neuroblastomas were treated with intra-tumoral injections of CpG-ODN, resulting in tumor inhibition and tumor rejection in one-third of the animals. Immunocytochemistry and Western blot studies revealed no specific anti-neuronal antibodies. None of the animals developed neurological disabilities and histological studies of the nervous system were normal. CpG-ODN can therefore trigger neuroblastoma rejection without inducing neurological paraneoplastic disease.
Insights
CpG-ODN treatment effectively rejected neuroblastomas in mice. Importantly, this immunostimulatory therapy did not trigger harmful autoimmune reactions affecting the nervous system, even in long-term survivors.
Area of Science:
- Immunology
- Neuro-oncology
- Cancer immunotherapy
Background:
- CpG-ODN are potent immune stimulants used in clinical trials.
- Concerns exist regarding potential autoimmune side effects, particularly neurological paraneoplastic diseases.
Purpose of the Study:
- To investigate if CpG-ODN-induced tumor rejection causes autoimmune reactions against the nervous system.
- To assess neurological safety during acute tumor rejection and long-term survival.
Main Methods:
- Mice with established neuroblastomas received intra-tumoral CpG-ODN injections.
- Immunocytochemistry and Western blot analyzed for anti-neuronal antibodies.
- Neurological function and histology were evaluated.
Main Results:
- CpG-ODN treatment inhibited tumors and led to rejection in one-third of mice.
- No specific anti-neuronal antibodies were detected.
- Animals showed no neurological disabilities or histological abnormalities in the nervous system.
Conclusions:
- CpG-ODN can induce neuroblastoma rejection.
- This immunotherapy does not appear to induce neurological paraneoplastic disease.